Grandfield & Dodd LLC Takes $598,000 Position in West Pharmaceutical Services, Inc. $WST

Grandfield & Dodd LLC acquired a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,667 shares of the medical instruments supplier’s stock, valued at approximately $598,000.

A number of other institutional investors have also recently modified their holdings of WST. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter worth about $25,000. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services in the second quarter worth about $25,000. Cornerstone Planning Group LLC boosted its holdings in shares of West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 50 shares during the last quarter. Bayban bought a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $27,000. Finally, Private Trust Co. NA grew its holdings in West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Down 0.8%

Shares of West Pharmaceutical Services stock opened at $346.69 on Tuesday. The stock has a market cap of $24.40 billion, a price-to-earnings ratio of 44.39, a PEG ratio of 2.44 and a beta of 1.15. The firm’s 50-day moving average is $347.00 and its two-hundred day moving average is $296.89. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. West Pharmaceutical Services’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is presently 11.27%.

Wall Street Analyst Weigh In

WST has been the subject of a number of recent analyst reports. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Evercore restated an “outperform” rating and set a $425.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 27th. KeyCorp lifted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Stephens reiterated an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Finally, Morgan Stanley upped their price target on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.